Filing Details
- Accession Number:
- 0001867096-22-000131
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-12-14 16:11:11
- Reporting Period:
- 2022-12-13
- Accepted Time:
- 2022-12-14 16:11:11
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1867096 | Xeris Biopharma Holdings Inc. | XERS | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1531178 | R Paul Edick | C/O Xeris Biopharma Holdings, Inc. 180 N. Lasalle Street, Suite 1600 Chicago IL 60601 | See Remarks | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-12-13 | 20,000 | $1.45 | 1,528,064 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 33,430 | Indirect | By: Paul R. Edick 2008 Revocable Trust u/d/t dated 6/25/2018 |
Footnotes
- The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.